HANGZHOU, China and LONDON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the positive topline results of its oral small-molecule GLP-1 receptor agonist MDR-001 in adults with overweight or obesity. Using an optimized once-daily (QD) regimen, MDR-001 achieved a body weight reduction of 8.9% over 12 weeks, compared to 0.6% in the placebo group (Pwith a favorable safety and tolerability profile.Phase Ib (12-week) QD Study DesignThis clinical study was "A randomized, double-blind, placebo-controlled Phase Ib trial to evaluate the efficacy and safety of small molecule MDR-001 tablets administered orally for 12 weeks in adults with overweight or obesity." The study was designed to optimize titration strategies to improve gastrointestinal tolerability, and maximize weight loss efficacy during long-term treatment. This dose regimen was achieved by employing a rapidly titrating to the target dose utilizing a once-daily (QD) administration.A ...Full story available on Benzinga.com